Summary
Eighty-one women with psychosis of schizophrenic and paranoid type were assigned to a double-blind study comparing the clinical effects of melperone (l00 mg × 3) and thiothixene (10 mg × 3). The antipsychotic effect was evaluated by clinical rating according to the CPRS and the NOSIE-30 scales before and after 2 and 4 weeks of drug treatment. A satisfactory interrater reliability was obtained for the CPRS. Significant correlation was also found between the CPRS and NOSIE ratings.
Treatment with both drugs was associated with significant reductions in morbidity as estimated by several measures of therapeutic effect from the CPRS, by the NOSIE scale and by global ratings. There were no marked differences at any rating time point between the drugs in this regard. There were more extrapyramidal side effects in the thiothixene group than in the melperone-treated patients.
The results encourage the use and further evaluation of melperone in the treatment of psychotic patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., Sedvall, G.: A comprehensive psychopathological rating scale. Acta Psychiatr. Scand. [Suppl.] 271 (1978) (The scale has been translated into German by Woggon, B., Storck, U., Droehse, B., 1978, unpublished)
Bishop, M. P., Fulmer, T. E., Gallant, D. M.: Thiothixene versus trifluoperazine in newly admitted schizophrenic patients. Curr. Ther. Res. 8, 509–514 (1966)
Bjerkenstedt, L., Gullberg, B., Härnryd, C., Sedvall, G.: Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene. Arch. Psychiatr. Neurol. Sci. 224, 107–118 (1977a)
Bjerkenstedt, L., Eneroth, P., Härnryd, C., Sedvall, G.: Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic women. Arch. Psychiatr. Neurol. Sci. 224, 281–293 (1977b)
Bleuler, M.: Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken und Familiengeschichten. Stuttgart: G. Thieme 1972
Bleuler, P. E.: Dementia praecox oder die Gruppe der Schizophrenien. Leipzig: Deutiche 1911
Burnett, G. B., Little, S. R. C. J., Graham, N., Forrest, A. D.: The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial. Dis. Nerv. Syst. 36, 625–629 (1975)
Christensen, J. A., Hernestam, S., Lassen, J. B., Sterner, N.: Pharmacological and toxicological studies on γ-(4-methylpiperidino)-p-fluorobutyrophenone (FG 5111)—a new neuroleptic agent. Acta Pharmacol. Toxicol. (Kbh.) 23, 109–132 (1965)
Clark, M. L., Huber, W. K., Charalampous, K. D., Serafetinides, E. A., Trousdale, W., Colmore, J. P.: Drug treatment in newly admitted schizophrenic patients. Arch. Gen. Psychiatry 25, 404–409 (1971)
Crane, G. E.: The prevention of tardive dyskinesia. Am. J. Psychiatry 134, 756–758 (1977)
Cronholm, B., Schalling, D., Åsberg, M.: Development of a rating scale for depressive illness. In: Pharmacopsychiatry, Vol. 7, P. Pichot, ed., pp. 139–150. Paris: Karger 1974
Engstrand, E.: Buronil og promazin behandling av senildemente. (Buronil and promazine in the treatment of senile dementia.) Nord. Psykiatr. Tidsskr. 21, 234–240 (1967)
Fyrö, B., Linder, J., Petterson, U.: A double-blind study of the antidepressive effect of lithium and clomipramine (to be published 1979)
Gallant, D. M., Bishop, M. P., Timmons, E., Gould, A. R.: Thiothixene (P-4657B): A controlled evaluation in chronic schizophrenic patients. Curr. Ther. Res. 8, 153–158 (1966)
Gross, H., Haberler, H.: Klinische Erfahrungen mit Methylperon (Buronil®), einem neuen Butyrophenonderivat. Int. Pharmacopsychiatry 5, 44–53 (1970)
Härnryd, C., Bjerkenstedt, L., Lindholm, H., Ljungberg, L.: En kontrollerad klinisk prövning av Buronil® och haloperidol vid förvirringstillstånd hos äldre patienter. (A controlled clinical study of Buronil and haloperidol in senile confusion.) Nord. Psykiatr. Tidsskr. 28, 469–472 (1974)
Haugen, T.: Buronil®, et nyt butyrofenonderivat ved akutte psykiatriska lidelser. (Buronil, a new butyrophenone derivative in acute psychiatric illnesses.) Ugeskr. Laeger. 129, 1194–1197(1967)
Honigfeld, G., Gillis, R. D., Klett, C. J.: NOSIE-30: A treatment-sensitive ward behavior scale. Psychol. Rep. 19, 180–182 (1966)
Jacobsson, L., Knorring, L. v., Mattsson, B., Perris, C., Rapp, W., Edenius, B., Kettner, B., Magnusson, K. E., Villemoes, P.: Controlled trial of penfluridol and thiothixene in the maintenance treatment of chronic schizophrenic syndromes. Acta Psychiatr. Scand. 54, 113–124(1976)
Kellam, A. M. P., Jones, K. S.: A double blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy. Acta Psychiatr. Scand. 37, 174–185 (1971)
Klein, D. F., Ross, D. C., Feldman, S.: Analysis and display of psychopharmacological data. J. Psychiatr. Res. 12, 125–147 (1975)
Lehmann, E. L.: Nonparametrics. Holden-Day 1975
May, P.: Treatment of schizophrenia. New York: Science House 1968
Montgomery, S., Åsberg, M.: A new depression scale designed to be sensitive to change. British J. Psychiat. Psychiat. (in press, 1978)
Nørgård, A., Tingsgaard, P., Nielsen, I. L.: Buronil ved senil konfusion og uro. (Buronil in senile confusion and anxiety.) Nord. Psykiatr. Tidsskr. 21, 240–244 (1967)
Olsson, S.-O., Passwall, N., Ressum, H.: In vitro autonomic effects of four neuroleptics: Chlorpromazine, haloperidol, melperone and thioridazine. Acta Pharmacol. Toxicol. (Kbh.) 41 [Suppl. 4], 66 (1977)
Overall, J. E., Hollister, L. E., Dalai, S. N.: Psychiatric drug research. Arch. Gen. Psychiatry 16, 152–161 (1967)
Overall, J. E., Klett, C. J.: Applied multivariate analysis. New York: McGraw-Hill 1972
Pinard, G., Prénoveau, Y., Fliesen, W., Elie, R., Bielman, P., Lamontagne, Y., Tétreault, L.: Pimozide: A comparative study in the treatment of chronic schizophrenic patients. Int. J. Clin. Pharmacol. 6, 22–27 (1972)
Schulsinger, F., Kirkegaard, A., Nielsen, S. K., Poulsen, H., Vangtorp, A., Gjeddebaek, N. F.: Kliniske forsøg med et nyt butyrofenonderivat, Buronil® (FG5111) ved svaer kronisk skizofreni. (Clinical trials with a new butyrophenone derivative, Buronil, in severe chronic schizophrenia.) Nord. Med. 73, 605–609 (1965)
Simpson, G. M., Angus, J. W. S.: A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. [Suppl.] 212 (1970)
Walcher, W.: Klinische Untersuchungen mit dem Butyrophenonderivat ‘Buronil.’ Pharmacopsychiatry 4, 59–66 (1970)
Weissman, A.: Chemical, pharmacological and metabolic considerations on thiothixene. In: Thiothixene and the thioxanthenes, I. S. Forrest, C. J. Carr, E. Usdin, eds., pp. 1–10. New York: Raven 1974
Wode-Helgodt, B., Borg, S., Fyrö, B., Sedvall, G.: Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr. Scand. 58, 149–173 (1978)
Wode-Helgodt, B., Nybäck, H., Wiesel, F., Sedvall, G.: Monoamine metabolites and prolactin in the cerebrospinal fluid of healthy volunteers as compared with psychotic patients. Acta Psychiatr. Scand. (to be published 1979)
World Health Organization: The international pilot study of schizophrenia (1973)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bjerkenstedt, L., Härnryd, C., Grimm, V. et al. A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch. Psychiatr. Nervenkr. 226, 157–172 (1978). https://doi.org/10.1007/BF00341708
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00341708